Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSNFree Report) in a research report released on Friday morning,RTT News reports. They currently have a $4.00 price objective on the stock, down from their prior price objective of $7.00.

Separately, Citigroup started coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.57.

View Our Latest Report on MRSN

Mersana Therapeutics Stock Down 44.6 %

Mersana Therapeutics stock opened at $0.72 on Friday. Mersana Therapeutics has a 52 week low of $0.69 and a 52 week high of $6.28. The stock has a market cap of $88.94 million, a price-to-earnings ratio of -1.18 and a beta of 1.43. The company’s 50-day moving average price is $1.97 and its two-hundred day moving average price is $1.88. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. The business had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business’s revenue for the quarter was up 63.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.35) earnings per share. On average, analysts expect that Mersana Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Trading of Mersana Therapeutics

A number of hedge funds have recently bought and sold shares of MRSN. US Bancorp DE purchased a new stake in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Mersana Therapeutics in the third quarter worth $34,000. Intech Investment Management LLC purchased a new stake in shares of Mersana Therapeutics during the 3rd quarter worth about $52,000. Quarry LP bought a new position in Mersana Therapeutics during the third quarter valued at approximately $57,000. Finally, Algert Global LLC bought a new position in shares of Mersana Therapeutics during the 2nd quarter valued at $90,000. 93.92% of the stock is owned by hedge funds and other institutional investors.

About Mersana Therapeutics

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Featured Articles

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.